Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

- Read more about Cipla to commercialize BioQ’s Ropivacaine Infusion System in India
BioQ Pharma and Cipla the signed of a strategic distribution, supply and development agreement for the registration and commercialization of BioQ Pharma's Ropivacaine infusion pharmaceutical in India.

[adsense:336x280:8701650588]
- Read more about BioQ Pharma Enter into an Agreement with Cipla
BioQ Pharma Incorporated, a specialty pharmaceutical company focused on the development and commercialization of single-use, large-volume ready-to-use infusible pharmaceuticals, and Cipla Limited, “Cipla,” a global pharmaceutical company that uses cutting edge technology and innovation to meet the everyday needs of all patients, announced the signing of a strategic distribution, supply and development agreement for the registration and commercialization of BioQ Pharma's Ropivacaine infusion pharmaceutical in India.
- Read more about Gilead Get FDA Priority Review Designation for Sofosbuvir/Velpatasvir
Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted priority review to the company’s New Drug Application (NDA) for an investigational, once-daily fixed-dose combination of the nucleotide analog polymerase inhibitor sofosbuvir (SOF)
- Read more about Lupin Launches Generic Ortho Tri-Cyclen® Lo Tablets in the US
Pharma Major Lupin Limited (Lupin) announced that its US subsidiary Lupin Pharmaceutical Inc. has launched its Tri-Lo-Marzia™ Tablets (Norgestimate and Ethinyl Estradiol Tablets USP, 0.180 mg/0.025 mg, 0.215 mg/0.025 mg, and 0.250 mg/0.025 mg) having received approval from the United States Food and Drug Administration (FDA) to market a generic equivalent of Janssen Pharmaceuticals Inc. (Janssen) Ortho Tri-Cyclen® Lo Tablets, (Norgestimate and Ethinyl Estradiol Tablets USP, 0.180 mg/0.025 mg, 0.215 mg/0.025 mg, and 0.250 mg/0.025 mg).
- Read more about Pre registration require for CDSCO's SUGAM Portal
For security purposes and to avoid spam health ministry decided that the applicants have to pre-register themselves on online licensing portal - the “SUGAM”. This portal is intended for those who desire to file applications for various services rendered by Central Drugs Standard Control Organization (CDSCO).
- Read more about Novartis Pharmaceuticals collaborates with Qualcomm in digital innovation with the Breezhaler(TM) inhaler device to treat COPD
Novartis announced today a collaboration with Qualcomm Incorporated through its subsidiary, Qualcomm Life, Inc., in digital innovation with the Breezhaler(TM) inhaler device to treat COPD. Under this collaboration, Qualcomm Life will provide the technology solution for the connectivity of the next generation of the Breezhaler(TM) inhaler, a device used for Novartis' portfolio of COPD treatments of Onbrez(TM) Breezhaler Seebri(TM) Breezhaler, and Ultibro(TM) Breezhaler, the leading LABA/LAMA treatment.
- Read more about Anti-depressants during pregnancy can increase birth defects risk
Using a medication prescribed to treat conditions including depression, obsessive-compulsive disorder, anxiety and post-traumatic stress disorder during the first trimester of pregnancy may increase newborns' risk of heart defects, says a study.
- Read more about High blood sugar levels could increase BP
Increased sugar levels in blood change the behaviour of blood vessels making them contract more strongly than normal which could result in higher blood pressure and increase the risk of heart attack complications, a study says.
- Read more about Gene thought to suppress cancer may not work for all tumours
A gene that is known to suppress the growth and spread of many types of cancer has the opposite effect in some forms of colorectal cancer, says a study led by an Indian-origin scientist.
- Read more about Baxalta and Symphogen Establish Strategic Collaboration to Accelerate Innovation in Immuno-Oncology
Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, and Symphogen, a private biopharmaceutical company developing recombinant antibodies and antibody mixtures, announced a broad strategic immuno-oncology collaboration.